Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer

Natalie Hartmann¹, Nathalia A Giese¹, Thomas Giese², Isabel Poschke³, Rienk Offringa³, Jens Werner¹, Eduard Ryschich¹
¹Department of General Surgery, University of Heidelberg, Heidelberg, Germany
²Department of Immunology, University of Heidelberg, Heidelberg, Germany
³Department of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany

Running title: Contact Guidance Controls T-cell Migration in PDAC

Keywords: Pancreatic cancer; Cell matrix interaction; Collagen; T cells; Migration

Grant Support: The project was funded by Deutsche Forschungsgemeinschaft (to E. Ryschich, RY20/9-1).

Corresponding Author:
Eduard Ryschich, University of Heidelberg, Department of General Surgery, Im Neuenheimer Feld 365, 69120 Heidelberg, Germany. Phone: +49-6221-56-6110; Fax: +49-6221-56-4208; E-mail: eduard.ryschich@med.uni-heidelberg.de

Disclosure of Potential Conflicts of Interest: No potential conflicts of interest were disclosed by the authors.

Words: 4077; Figures: 6
Abstract

**Purpose:** Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive collagen-rich stroma. T cells that infiltrate pancreatic cancers frequently become trapped in the stroma and do not contact tumor cells. Here we aimed to analyze how chemokines and extracellular matrix (ECM) collagen interact in mediating T-cell infiltration in PDAC.

**Experimental design:** T-cell distribution and ECM structure within tumors were analyzed. Chemokine concentrations in human PDAC were compared to the levels of immune cell infiltration. We assessed the influences of selected chemokines and collagen on directed and random T-cell movement using *in vitro* migration systems.

**Results:** PDAC overproduced several T-cell-active chemokines, but their levels were not correlated with intratumoral T-cell infiltration. In the absence of collagen, directed migration of activated T cells was induced by chemokines. Interestingly, collagen itself promoted high migratory activity of T cells, but completely abolished chemokine-guided movement. This effect was not altered by a β1-integrin blocking antibody. Activated T cells actively migrated in low-density collagen matrices, but migration was inhibited in dense collagen. Accordingly, T cells were heterogeneously distributed in the pancreatic cancer stroma, with the majority residing in areas of low-density collagen far from tumor clusters.

**Conclusion:** The excessive desmoplasia in PDAC promotes T-cell migration by contact guidance, which abrogates tumor-cell-directed movement. Furthermore, dense collagen networks represent a physical barrier, additionally rearranging T-cell distribution to favor tumor stroma. These mechanisms are mainly responsible for intrastromal T-cell trapping in pancreatic cancer and may hinder the development of T-cell-based immunotherapies.
**Translational relevance**

Extensive desmoplasia is an important feature of PDAC, which contributes to its therapy resistance. PDACs are infiltrated by T cells that predominantly become trapped in the stroma and thus fail to reach the tumor. The present study demonstrates that the prevailing force of contact guidance supports stromal accumulation of T cells by abrogating intratumoral chemokine-guided T-cell migration and misdirecting them away from tumor cells. As the predominant stromal component in PDAC, collagen type I may additionally form a physical barrier that limits T cell access to tumor cells. Misguidance of T cells by tumor stroma may impede antitumoral immune responses, thus contributing to the poor prognosis of this malignant disease. The strong desmoplastic reaction in pancreatic cancer may suppress or block the efficacy of T-cell-based strategies, including adoptive transfer and antibody treatment. Furthermore, matrix-degrading treatment approaches might significantly improve the efficacy of endogenous anti-tumor immune responses and T-cell-based immunotherapies.
Introduction

Pancreatic ductal adenocarcinoma (PDAC), one of the most common causes of cancer death worldwide, is usually diagnosed at an advanced stage and has an overall five-year survival rate of below 5% (1). The poor outcomes of PDAC reflect our current limited understanding of this complex and highly aggressive tumor. There is an urgent need for the development of new treatment strategies, such as immunotherapeutic approaches.

The tumor microenvironment plays a decisive role in tumor defense and progression. In PDAC, the stroma is composed of multiple cell types—including fibroblasts, pancreatic stellate cells (PSCs), endothelial cells, and inflammatory cells—which secrete a variety of factors, such as extracellular matrix (ECM) components, cytokines, and chemokines (2). Collagen type I is the most abundant ECM protein in PDAC (3–5). PDAC is characterized by particularly strong desmoplasia—with the stromal fraction often exceeding the epithelial portion of the tumor—which is considered an important factor driving tumor progression and mediating chemotherapy resistance (2). Recent studies in mice show stromal depletion resulting in sensitization of PDAC to chemotherapeutic intervention (6–8).

The degree of T-cell infiltration has been identified as an important prognostic factor in various types of cancer. Strong infiltration, especially by cytotoxic CD8⁺ T cells, is usually associated with improved patient outcomes (9, 10). Human PDAC frequently induces an immune response resulting in marked T-cell infiltration (11, 12). However, the vast majority of tumor-infiltrating T cells become trapped in the stroma and peritumoral tissue by some yet unknown mechanism, and thus the T cells do not reach the cancer cells in sufficient numbers (12, 13).

T-cell migration into and within tumors is guided by chemokines and ECM proteins (14, 15). Several of the most important chemokines in this process include
stromal cell-derived factor-1 (SDF-1, CXCL12), IFNγ-inducible protein 10 (IP-10, CXCL10), and macrophage inflammatory protein-1β (MIP-1β, CCL4) along with their corresponding chemokine receptors (CRs): CXC chemokine receptor (CXCR) 4, CXCR3, and CC chemokine receptor (CCR) 5 (16–18). In particular, CXCR3 and CCR5 are important mediators of T-cell homing to sites of inflammation (19). These and other CRs have been implicated in T-cell recruitment into a variety of cancer entities, and the corresponding chemokines are often overexpressed (14, 20–22).

Two types of directed T-cell movement have been identified: chemotaxis, which is induced by soluble, freely diffusing compounds, and haptotaxis, which is cell migration towards a concentration gradient of ECM-bound chemokine (15).

In addition to chemokine-induced migration, T cells move through the three-dimensional (3D) ECM by contact guidance, which is described as migration along ECM fibers and squeezing through matrix gaps, following the path of least resistance (15). In contrast to migration across two-dimensional ECM, which requires interactions between leukocyte integrins and the substrate, contact guidance is an amoeboid-like type of migration that is usually independent of integrins and matrix-metalloproteinases (15, 23, 24). ECM structures can provide a scaffold that supports 3D T-cell migration, but dense ECM fiber alignment can create non-permissive matrix regions that exclude T cells. Several studies have demonstrated such non-permissive stromal areas in human tumors, which may complicate anti-tumor immune responses (25–27). Here we investigated the mechanisms controlling intratumoral T-cell migration in PDAC in terms of chemokines and contact guidance, and determined whether and how these mechanisms contribute to immune evasion of PDAC.

Materials and Methods

Patients and tissue samples
This study included patients undergoing surgery for pancreatic carcinoma in the Department of Surgery at the University of Heidelberg. The protocol was approved by the local ethics committee, and informed consent was obtained from all patients, in accordance with the Helsinki declaration. Normal pancreatic specimens were obtained from donor organs in cases where no suitable recipient was found through the Eurotransplant program. Tissue samples were snap-frozen and stored in liquid nitrogen.

**Cell culture and T-cell activation**

Cell lines were grown in complete RPMI 1640 (cc-pro, Oberdorla, Germany) supplemented with 10% fetal calf serum (FCS) (PAA, Pasching, Austria), 2 mM L-glutamine, 20 U/mL penicillin, and 0.1 mg/mL streptomycin (cc-pro). For T-cell culture, we added 1 mM sodium pyruvate (Biochrom AG, Berlin, Germany) and 0.05 mM β-mercaptoethanol (Gibco, Darmstadt, Germany). Boyden chamber assays were performed in phenol red-free RPMI 1640 (cc-pro) supplemented with 0.5 or 1% FCS (PAA), 0.2% cell culture-tested bovine serum albumin (BSA) (Sigma-Aldrich, Munich, Germany), 2 mM L-glutamine, 20 U/mL penicillin, 0.1 mg/mL streptomycin (cc-pro), 1 mM sodium pyruvate (Biochrom AG), and 0.05 mM β-mercaptoethanol (Gibco). Cell cultures were incubated at 37°C in a humidified atmosphere with 5% CO₂.

Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors by density gradient centrifugation using Biocoll (Biochrom AG). From these PBMCs, we isolated unstimulated T cells by magnetic-activated cell sorting (MACS) using CD3 Microbeads and LS columns (Miltenyi Biotech, Bergisch-Gladbach, Germany) following the manufacturer’s instructions. For activation, PBMCs were stimulated for 24 h with 12.5 µg/mL concanavalin A (Calbiochem, Darmstadt, Germany) or for 48 h with 3 µg/mL plate-bound anti-CD3 (clone OKT3) and 1 µg/mL
plate-bound anti-CD28 (clone CD28.2) (eBioscience, Frankfurt am Main, Germany). The cells were next cultured for 5–7 days in the presence of 50 U/mL interleukin-2 (IL-2) (PeproTech, Hamburg, Germany). The percentage of CD3\(^+\) cells was determined by flow cytometry, and was >95% in all samples.

Single-cell suspensions were obtained from tumor tissues by scratching the tissue surface with a scalpel and passing the suspension through a 70-µM cell strainer (BD Falcon, Heidelberg, Germany). The cells were immediately analyzed by flow cytometry. For \textit{in vitro} migration assays, T cells were extracted from tumors by incubating tissue pieces in high-dose IL-2 (6000 U/mL). The cells were subsequently expanded in the presence of 30 ng/mL anti-CD3 antibody (clone OKT3; eBioscience) and a mixture of allogeneic PBMCs from three donors, which had been inactivated by an irradiation dose of 40 Gy.

### Analysis of tissue chemokine levels

Chemokine and CR mRNA levels in total tissue lysates were determined by quantitative real-time polymerase chain reaction (qRT-PCR) as described previously (28, 29). All materials and equipment for RNA and cDNA preparation were obtained from Roche (Mannheim, Germany) and used following the manufacturer’s instructions. Target-specific and housekeeping gene cyclophilin B (CPB)-specific primers were purchased from Search LC (Heidelberg, Germany).

To determine chemokine protein levels, snap-frozen tissue was cut into 50-µM cryosections, and homogenized using the Bioplex Cell Lysis Kit (BioRad, Munich, Germany) following the manufacturer’s instructions. Chemokine concentrations were then assessed using Bioplex technology (BioRad) according to the manufacturer’s instructions.
Immunohistochemistry, immunofluorescence, and second harmonic generation (SHG) microscopy

For immunohistochemistry, 7 µM acetone-fixed cryosections were stained overnight at 4°C with antibodies against CD3 (clone F7.2.38; Dako, Hamburg, Germany), CXCR4 (clone 44716; R&D Systems, Wiesbaden-Nordenstadt, Germany), CXCR3 (polyclonal; Acris, Herford, Germany), or CCR5 (clone eBioT21/8; eBioscience) or with the corresponding isotype controls in TBS with 1% BSA. Immune complexes were developed using the LSAB+ detection system (Dako) according to the manufacturer’s instructions. Sections were counterstained with hematoxylin (Roth, Karlsruhe, Germany) and analyzed under a Leica DMRB bright-field microscope (Leica, Wetzlar, Germany). In the same samples used for Bioplex analysis (n = 29), we assessed the densities of CD3+ and CR-expressing cells by direct leukocyte counting in three random microscopic fields (total area: 0.27 mm²). These results were expressed using the following scale: 0 = absent, 1 = low, 2 = moderate, 3 = high, and 4 = very high infiltration. In 100 tumor samples, we determined maximum CD3+ infiltration (Fig. 1A) by identifying the microscopic areas with maximum T-cell accumulation and grading the T-cell infiltration in these areas using the above scale, as described previously (13, 30).

For laser-scanning confocal microscopy (LSCM), cryosections from three tumor samples were fixed with 7 µM acetone, and then stained with antibodies against collagen type I (polyclonal; Acris) and cytokeratin-7 (clone OV-TL 12/30; Zytomed, Berlin, Germany), followed by anti-rabbit-DyLight649 (BioLegend, Fell, Germany) and anti-mouse-DyLight550 (Biomol, Mannheim, Germany), and finally with anti-CD3-AlexaFluor488 (clone HIT3a; BioLegend), each for 1 h at room temperature. Sections were counterstained with DAPI and analyzed using an A1R confocal microscope (Nikon, Düsseldorf, Germany).
For SHG microscopy, cryosections from seven tumor samples were fixed with 20 µM 4% paraformaldehyde. These sections were then stained for 5 h with an antibody against cytokeratin-7 (clone OV-TL 12/30; Zytomed), followed by anti-mouse-AlexaFluor568 (Invitrogen, Darmstadt, Germany) for 5 h, and finally with anti-CD3-AF488 (clone HIT3a; BioLegend) overnight at 4°C. Fluorescence and collagen SHG signals were detected using a TriM Scope 2-photon microscope (LaVision, Göttingen, Germany).

**Flow cytometry**

Cells (2 × 10^5/sample) were stained for 30 min in PBS containing 0.1% BSA, 0.05% sodium azide, and fluorescent dye-conjugated antibodies against CD3 (clone OKT3), CD4 (clone SK3), CD8 (clone OKT8), CD45RO (clone UCHL1), CCR7 (clone 3D12), CXCR4 (clone 12G5), CD49b (clone eBioY418) (all purchased from eBioscience), CD29 (clone TS2/16; BioLegend), CCR5 (clone 45531; R&D Systems), and CXCR3 (clone 1C6; BD Biosciences) or the corresponding isotype controls. Dead cells were excluded by 7-AAD staining (Sigma-Aldrich). Data were acquired on an LSR II flow cytometer (Beckton Dickinson) and analyzed using FlowJo software (Tree Star, Ashland, OR, USA).

**Migration systems**

For Boyden chamber assays, cells were serum-starved overnight at 37°C in medium containing 0.5% FCS. Cells (2 × 10^6/mL) were labeled with 4 µM calcein AM (Santa-Cruz Biotechnology, Heidelberg, Germany) for 1 h at 37°C. The cells and chemokine solutions were prepared in serum-reduced medium (1% FCS). Cells (1 × 10^4/well) were seeded in the upper wells of HTS Transwell-96 plates (Corning, Kaiserslautern, Germany). Migration was induced with 100 ng/mL SDF-1 or IP-10.
(PeproTech). After 3 h, migration was measured as fluorescence intensity in the lower wells using a FLUOstar OPTIMA imager (BMG Labtech, Ortenberg, Germany). Where indicated, the upper wells were coated with 0.1 mg/mL collagen type I (Serva, Heidelberg, Germany) for 3 h at 37°C, and then dried overnight at room temperature. For 3D migration at uniform chemokine distribution, a collagen type I solution (Serva) was used to produce collagen matrices of varying density with or without added chemokine (SDF-1 or IP-10, 100 ng/mL). These matrices were allowed to polymerize in 96-well flat-bottom plates for 45 min at 37°C in a humidified chamber. Cells in PBS were then seeded at a density of $1 \times 10^5$/well on the gels, and examined using an Axio Observer.Z1 bright-field microscope (Zeiss). Migration was assessed by measuring the z-distance from the top of the gel to the migration front after 3 h, or by counting the cells at $\Delta z = 1$ mm after 12 h.

For 3D migration in the presence of a chemokine gradient, cells ($9 \times 10^6$/mL) were seeded in 1 mg/mL collagen type I gels in a µ-slide chemotaxis 3D (Ibidi, Martinsried, Germany) following the manufacturer’s instructions. The cells were then exposed to gradients of SDF-1 or IP-10 (maximum: 100 ng/mL). Migration was recorded once per minute for 1 h by time-lapse microscopy using an Axio Observer.Z1 bright-field microscope (Zeiss). A constant temperature of 37°C and constant 5% CO$_2$ level were ensured using heatable incubation chambers and temperature/CO$_2$ control units (Pecon, Erbach, Germany). The percentage of migrating cells was determined and directional migration was analyzed by manually tracking 20 individual cells per condition and calculating the percentage of cells oriented towards the chemokine. As an additional measure of directional migration, the mean chemotropism index (MCI) was calculated according to Tharp et al. (31).

To analyze the ability of collagen to bind chemokines, 100 ng/mL of SDF-1 or IL-10 was added to 100 µL of collagen matrix mixture prior to polymerization. After
polymerization, 100 µL PBS was added on the matrix. ELISA was used to measure the concentration of non-bound chemokine released into the PBS over 5 hours at 37°C. The same chemokine solution in PBS without matrix was used as a reference.

For some experiments, $1 \times 10^6$ fluorescently labeled T cells were pretreated with 5 µg anti-β1-integrin blocking antibody (clone 6S6; Millipore, Darmstadt, Germany) for 15 min at 37°C. A FLUOstar OPTIMA fluorimeter (BMG Labtech) was used to determine blocking efficiency of cell attachment to collagen-coated plates (15 min at 37°C) before and after treatment. The same method was utilized to measure attachment of T cells to collagen-coated plates that were pre-treated with 100 ng/mL of SDF-1 or IP-10 for 30 min at 37°C ($n = 3$).

Statistics

The Mann-Whitney test was used to determine the statistical significance for qRT-PCR and Bioplex data. Migration data were compared by analysis of variance. A $P$ value of <0.05 was considered to be significant.

Results

PDAC-infiltrating T cells mainly accumulate in the tumor stroma and express the CRs CXCR3, CXCR4, and CCR5

T-cell infiltration and distribution in PDAC tissue were studied by immunohistochemistry. Approximately 50% of the tumor samples were not or rarely infiltrated by CD3+ cells (grade 0–1), while the other half showed marked infiltration (grade 2–4). T cells were mainly localized in the tumor stroma and rarely contacted tumor cells (Fig. 1A and B).

Next, qRT-PCR was used to analyze the expressions of CRs related to T-cell homing. In tumor tissue compared to in normal pancreas samples, CXCR4 and
CXCR3 mRNA levels were increased by 19- and 25-fold, respectively, \((P < 0.001)\), while CCR5 mRNA levels did not significantly differ between groups (Fig. 2A). Flow cytometric analysis of the activation status and CR profile of PDAC-infiltrating T cells revealed that, immediately after isolation or after \textit{in vitro} expansion, tumor-derived T cells displayed an effector/memory phenotype \((\text{CD}45\text{RO}^+ \text{CCR}7^-)\) and mainly expressed the CRs CXCR4 and CXCR3 and, to some extent, CCR5 (Fig. 2B and C). This phenotype could be mimicked in peripheral blood-derived T cells (PBTs) by standard activation protocols (Suppl. Fig. 1A and B).

**Chemokine levels are dysregulated in PDAC, but do not correlate with T-cell infiltration**

Next, production of the corresponding T-cell-active chemokines SDF-1, IP-10, and MIP-1\(\beta\) was assessed using qRT-PCR and Bioplex technology. All three chemokines were expressed in both normal pancreas and pancreatic cancer samples. In tumors compared to in non-malignant tissue, IP-10 mRNA \((P < 0.001)\) and MIP-1\(\beta\) mRNA \((P = 0.002)\) expressions were upregulated by 9- and 15-fold, respectively, while SDF-1 mRNA expression was unchanged (Fig. 3A). At the protein level, IP-10 and MIP-1\(\beta\) were overexpressed in tumor tissue by 40- and 10-fold, respectively, \((P < 0.001)\). Interestingly, SDF-1 protein was also upregulated by 2-fold \((P = 0.022)\) in tumors compared to non-malignant tissue (Fig. 3B). However, immunohistochemical quantification of tumor-infiltrating \text{CD}3^- and CR-expressing cells revealed no correlations with the chemokine concentrations measured in the corresponding samples (Fig. 3C and D). Because CXCR4 and CXCR3 were elevated at the mRNA level and were predominantly expressed in tumor-infiltrating T cells, their corresponding ligands (SDF-1 and IP-10) were selected for T-cell migration studies.
Collagen matrices promote T-cell migration by contact guidance that abrogates chemokine-guided migration

To clarify whether contact guidance was an important determinant of T-cell migration in PDAC, we tested the chemotactic responses of activated T cells in the presence or absence of collagen type I. Activated PBTs responded well to SDF-1 and IP-10 in a Boyden chamber ($P \leq 0.001$ for medium alone vs. with SDF-1 or IP-10). Interestingly, this effect was completely abrogated when the membrane was coated with collagen type I ($P < 0.001$) (Fig. 4A). We next examined chemokine-induced T-cell migration in a collagen matrix using time-lapse microscopy. Without chemokines, non-activated PBTs displayed low migrational activity, which was strongly increased upon exposure to a gradient of SDF-1 ($P = 0.015$), but not IP-10 (Fig. 4B). This observation corresponded to non-activated PBTs displaying high surface expression of CXCR4, while CXCR3 expression was absent in this subpopulation (Suppl. Fig. 1B). Non-activated PBTs showed directional migration towards SDF-1 (MCI = +0.16; $P = 0.04$ for medium alone vs. SDF-1), but not IP-10 (MCI = −0.08; $P = 0.656$ for medium alone vs. IP-10). Activated PBTs and tumor-derived T cells showed higher basal migration in collagen matrices, which was not further enhanced by gradients of SDF-1 or IP-10 (Fig. 4B), despite CR expression (Fig. 2C and Suppl. Fig. 1B). Activated PBTs and tumor-derived T cells migrated in a random, chemokine-independent manner ($0.1 > \text{MCI} > −0.1$ in all cases) (Fig. 4E).

To differentiate between effects of the bound (haptotaxis) and soluble (chemotaxis) chemokine fractions, we studied the binding capacity of chemokines to collagen and their influence on T-cell adhesion. SDF-1 showed a high capacity to bind to collagen matrix during polymerization, although a fraction of SDF-1 remained unbound and was released into the soluble phase (Fig. 4C). IP-10 showed no binding
to collagen (Fig. 4C). Furthermore, T-cell adhesion to collagen-coated plates was not increased after pre-treatment with SDF-1 or IP-10 (Fig. 4D).

**Contact guidance migration of activated T cells is independent of β1-integrin**

α2β1-integrin was expressed on non-activated PBTs and upregulated after activation. It was also present on freshly isolated and *in vitro*-expanded tumor-derived T cells (Fig. 5A). Adhesion of untreated activated PBTs and tumor-derived T cells was 2- to 3-fold stronger than that of non-activated PBTs. Blocking β1-integrin reduced the adhesion of activated PBTs and tumor-derived T cells almost to the level of non-activated PBTs (*P* < 0.001) (Fig. 5B). Despite this rather strong effect on adhesion, β1-integrin inhibition did not enhance basal migration or restore the activated T-cell response to chemokines in the presence of collagen type I in the Boyden chamber (Fig. 5C). Similarly, activated PBT migration in a collagen type I matrix was indistinguishable in the presence or absence of a uniform chemokine concentration, which was independent of β1-integrin blockade (Suppl. Fig. 2). Total 3D migration of activated PBTs and tumor-derived T cells in the presence of a chemokine gradient was also unaltered upon treatment with the β1-integrin antagonist (Fig. 5D). Moreover, there was no significant effect on the directional migration of activated T cells (0.1 > MCI > −0.1 in all cases) (Fig. 5E).

**High-density collagen networks impede T cell–tumor cell contact in PDAC**

We next analyzed intratumoral T-cell localization relative to the local matrix density using LSCM (Fig. 6A) and SHG microscopy (Fig. 6B and C). Collagen type I was ubiquitously present in the tumor stroma (Fig. 6A). The stromal collagen fiber density was heterogeneous, but significantly higher near tumor cell clusters (Fig. 6C). Notably, T cells preferentially accumulated in areas of low collagen density. To
confirm the impact of the collagen structure on T-cell migration in vitro, we examined the efficiency of T-cell invasion into 3D collagen matrices of different densities. Maximum invasion occurred at the lowest collagen density (0.5 mg/mL). The migration distance and numbers of invading T cells were significantly reduced with increasing matrix density, and the highest collagen density (1.5 mg/mL) almost completely suppressed invasion (Fig. 6D).

**Discussion**

In the initial part of the present study, the T-cell distribution in pancreatic tumors was analyzed and assigned to tumor clusters or stromal compartments. Half of the tumor samples showed moderate or high T-cell infiltration. Of these samples, all exhibited stromal infiltration, while only 28% exhibited moderate T-cell numbers within tumor clusters. These results suggested that the stroma in PDAC might play an important role in guiding infiltrating T cells, which was investigated further.

We examined two mechanisms that potentially determine intratumoral T-cell localization: chemokine-induced migration and contact guidance. We found that several T-cell-specific chemokines were strongly overproduced in PDAC. However, we observed no relationship between chemokine levels and the degree of infiltration by T cells or CR-expressing cells, demonstrating a circumstantial role of chemokines in T-cell infiltration of PDAC.

Next, we investigated the differential effects of chemokines and collagen type I on T-cell migration in detail using various migration systems. Our results clearly demonstrated that collagen promoted T-cell migration by contact guidance, which strongly prevailed over chemokine-induced responses. This effect was attributable to activated T cells, but not non-activated T cells. Physiologically, these findings imply that the immune system produces functionally mature activated T cells expressing...
appropriate CRs, which are recruited to tumor sites, emigrate into tumor tissue from blood vessels, and are theoretically able to follow chemokine gradients. However, upon emigration, activated T cells contact the dense matrix of the pancreatic stroma, which switches their migrational mode from chemokine- to stroma-guided movement, thus misdirecting them from their migration toward tumor cells. Interestingly, SDF-1 can be bound by collagen matrix and may employ both hapto- and chemotactic signals, whereas IP-10 does not bind to collagen and may act as chemotactic agent. The above results demonstrate that the prevalence of matrix-guided migration over chemokine action is independent from the mode of chemokine-induced migration, e.g., haptotaxis or chemotaxis.

One potential molecular mechanism for controlling T-cell migration through collagen in PDAC may involve $\alpha_2\beta_1$-integrin, which reportedly mediates T-cell adhesion to collagen (32). We found that both non-activated and activated T cells expressed $\alpha_2\beta_1$-integrin, but only activated T cells efficiently adhered to collagen type I. This phenomenon may occur because integrins must switch to an active conformation to mediate adhesion, which can be induced by T-cell activation and chemokine exposure (33). $\beta_1$-integrin blockade efficiently reduced the adhesion of activated T cells to collagen-coated surfaces to the level observed in non-activated T cells; however, it did not restore their chemokine responsiveness in a collagen matrix. This observation is in line with results from human lung tumors, in which $\beta_1$-integrin blockade alters the migration of activated T cells on two-dimensional surfaces, but not in a 3D matrix (27). The ability of T cells to migrate through the ECM in an integrin-independent manner has been described previously (23). Our findings indicate that activated T-cell migration in collagen matrices occurs predominantly in a $\beta_1$-integrin-independent manner. Furthermore, they suggest that integrin-mediated adhesion to collagen is not the major factor determining the non-responsiveness of
activated T cells to chemokines in the presence of collagen. Although our present findings did not identify any additional molecular mechanisms of contact guidance by collagen, it has been previously described that contact guidance may involve low adhesive interactions between T cells and collagen (15).

The principle of contact guidance is that matrix fiber orientation and density provide a scaffold along which T cells can migrate, following the path of least resistance (15). This behavior is feasible because T-cell migration in the ECM occurs independently of matrix-degrading mechanisms (34). Furthermore, it has been demonstrated that T cells are less potent than neutrophils in migrating through dense ECM networks because of their limited capacity for nuclear deformation (35). The present study demonstrates that this principle can be applied to describe T-cell migration in PDAC. In vitro, the extent of T-cell invasion into a collagen matrix was negatively correlated with the matrix density. This observation corresponds well with our data from tumor samples, which showed preferential T-cell accumulation in stromal areas of lower collagen density. Similar findings were previously reported in a study of human lung cancer, demonstrating that T cells preferentially localize to regions of low matrix density and display decreased motility in dense matrix areas (27). Those authors concluded that increased collagen deposition around tumor clusters may act as a substantial mechanical barrier for T cells. However, our present findings only partially support these conclusions, as the collagen shield around tumor cell clusters is highly discontinuous, and there was only a slightly difference in collagen density between the tumor cell surroundings and T-cell areas.

A dense ECM is a major hindrance in chemotherapeutic treatment of pancreatic cancer. Recent studies have demonstrated that the therapeutic resistance of PDAC can be overcome by combining classical chemotherapy with matrix-degrading approaches, such as enzymatic degradation of hyaluronic acid (8, 36),
drug stabilization and stromal depletion by nab-paclitaxel (6, 37) or the hedgehog
signaling inhibitor IPI-926 (7, 38), or siRNA-mediated targeting of a collagen type I-
specific chaperone in PSCs (39). A phase II clinical trial has already demonstrated
beneficial effects of combinatorial therapy with gemcitabine and nab-paclitaxel on the
survival of pancreatic cancer patients (37).

We believe that the extensive desmoplasia in PDAC may also interfere with
efficient endogenous anti-tumor T-cell responses, and may impede T cell-based
immunotherapeutic approaches. Hence, combining T-cell immunotherapy with
matrix-degrading mechanisms might be a promising future treatment strategy. This
approach could be improved further by strategies that redirect T cells towards their
tumor cell targets. Therefore, there is a need to develop specific tools to target the
contact guidance of T cells.

In summary, the excessive desmoplastic reaction in pancreatic cancer
abrogates the chemokine-induced response of tumor-infiltrating T cells and switches
their movement mode to contact guidance. The prevalence of contact guidance
mediated by collagen fiber orientation along with the increased collagen density may
jointly account for the stromal trapping of T cells observed in PDAC. These
mechanisms may impede endogenous anti-tumor immune responses, and should be
considered in the development of T cell-based immunotherapies.
Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed by the authors.

Author Contributions

Conception and design: E. Ryschich

Methodology development: N. Hartmann, E. Ryschich, I. Poschke

Data acquisition: N. Hartmann, E. Ryschich, T. Giese

Data analysis and interpretation: N. Hartmann, E. Ryschich

Manuscript writing, review, and/or revision: N. Hartmann, E. Ryschich, N.A. Giese, T. Giese, I. Poschke, R. Offringa, J. Werner

Administrative, technical, or material support: N.A. Giese, R. Offringa, J. Werner

Study supervision: E. Ryschich

Grant Support

The project was funded by Deutsche Forschungsgemeinschaft (to E. Ryschich, RY20/9-1).

Acknowledgements

We thank Dr. N. Dross and Dr. C. Ackermann (Nikon Imaging Center, University of Heidelberg) for assisting with SHG microscopy and LSCM. We thank Dr. W. Gross for help with cell tracking and statistical analysis, and C. Bernardi for excellent technical assistance.
Footnotes

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).
References


crosstalk between pancreatic acini and macrophages during the clearance of
The ECM proteoglycan decorin links desmoplasia and inflammation in chronic
leukocyte adhesion to endothelium in normal pancreas and in pancreatic carcinoma
Neutrophil chemorepulsion in defined interleukin-8 gradients in vitro and in vivo. J
32. Goldman R, Harvey J, Hogg N. VLA-2 is the integrin used as a collagen receptor
34. Wolf K, Muller R, Borgmann S, Brocker EB, Friedl P. Amoeboid shape change
and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent
limits of cell migration: Control by ECM space and nuclear deformation and tuning by
36. Michl P, Gress TM. Improving drug delivery to pancreatic cancer: breaching the


Figure Legends

**Figure 1.** PDAC-infiltrating T cells mainly accumulate in the tumor stroma, and rarely contact tumor cells. A, Quantitative analysis of intratumoral CD3+ T-cell infiltration in human PDAC: 0 = absent, 1 = low, 2 = moderate, 3 = high, and 4 = very high infiltration. Almost 50% of tumor samples showed moderate or higher infiltration (n = 100). B, Representative images of immunohistochemistry showing different grades of stromal CD3+ infiltration.

**Figure 2.** PDAC-infiltrating T cells express CXCR3, CXCR4, and CCR5. A, Comparison of CR expression in normal pancreas (NP) and tumors (T) by qRT-PCR. Data are shown as the mean target copy numbers and SEM per 10,000 copies of the housekeeping gene CPB. CXCR4: n = 37 (NP), n = 61 (T); CXCR3: n = 22 (NP), n = 39 (T); CCR5: n = 4 (NP), n = 6 (T). *P < 0.05; **P < 0.001. Tumors showed higher expressions of CXCR4 and CXCR3. B and C, Flow cytometric analysis of T-cell phenotype (B) and CR expression (C) in freshly isolated (day 0) and cultured (day 14) tumor-derived T cells. Light red lines represent the isotype control, and dark red lines represent specific staining. Tumor-derived T cells displayed an effector/memory phenotype (CD45RO+ CCR7−) and mainly expressed the CRs CXCR4 and CXCR3 and, to some extent, CCR5. Representative samples are shown (total n = 3).

**Figure 3.** Chemokine levels are dysregulated in PDAC, but do not correlate with T-cell infiltration. A and B, Chemokine expression compared between normal pancreas (NP) and tumors (T) at the mRNA level by qRT-PCR (A), and at the protein level using Bioplex technology (B). A, Data are shown as mean target copy numbers and SEM per 10,000 copies of the housekeeping gene CPB. SDF-1: n = 39 (NP), n = 61
(T); IP-10: \( n = 24 \) (NP), \( n = 31 \) (T); MIP-1\( \beta \): \( n = 11 \) (NP), \( n = 5 \) (T). **\( P < 0.001 \). B, Data are shown as the amount of chemokine/total protein and SEM. \( n = 5 \) (NP), \( n = 29 \) (T). *\( P < 0.05 \); **\( P < 0.001 \). C, Representative images of immunohistochemical analysis of CD3\(^+\) and CR expression in cells from tumor samples. D, Quantitative analysis of infiltration by CD3\(^+\), CXCR4\(^+\), CXCR3\(^+\), and CCR5\(^+\) cells (\( n = 29 \) samples) and comparison with the chemokine levels in the corresponding patients. Infiltration grades: 0 = absent, 1 = low, 2 = moderate, 3 = high, and 4 = very high infiltration.

**Figure 4.** Collagen matrices promote T-cell migration by contact guidance, thus abrogating chemokine-induced migration. A, Migration of activated PBTs in a Boyden chamber in response to SDF-1 or IP-10 with or without collagen type I coating. Data presented as the mean and SD of three independent experiments. *\( P < 0.05 \); **\( P \leq 0.001 \). B, Migrational activity of non-activated PBTs, activated PBTs, and tumor-derived T cells in a collagen type I matrix in the presence of a chemokine gradient. The percentage of migrating cells/total cells is shown. Data are presented as the mean and SD of two to three independent experiments. *\( P < 0.05 \). C, Binding of SDF-1 and IP-10 to collagen matrix during matrix polymerization. SDF-1 was partially bound, whereas IP-10 was not bound (\( n = 3 \)). D, Adhesion of T cells to a collagen-coated surface that was pre-treated with chemokines. No significant differences were found (\( P > 0.05 \), \( n = 3 \)). Data are shown as percent related to the non-treated PBT\(_{na}\) and SD of three independent experiments performed in triplicate. E, Determination of directional migration of non-activated PBTs, activated PBTs, and tumor-derived T cells in a collagen type I matrix with a chemokine gradient. Colored lines represent individual cells. The percentage of cells oriented towards the chemokine-containing chamber (= –x) of one representative experiment (\( n = 2–3 \)) is indicated.
**Figure 5.** Contact guidance migration of activated T cells is independent of $\beta_1$-integrin. A, Flow cytometric analysis of $\alpha_2\beta_1$-integrin expression in non-activated PBTs, activated PBTs, and freshly isolated (day 0) and cultured (day 14) tumor-derived T cells. Light red lines represent the isotype control, and dark red lines represent specific staining. Representative samples are shown (total $n = 3$). B, Adhesion of non-activated PBTs, activated PBTs, and tumor-derived T cells to a collagen type I-coated surface with or without treatment with an anti-$\beta_1$-integrin blocking monoclonal antibody (mAb). Data are presented as the mean fluorescence intensity (MFI) and SD of seven (PBT$_{na}$ and PBT$_a$) or two (tumor-derived) independent experiments performed in triplicate. **$P < 0.001$. C, Migration of activated PBTs in a Boyden chamber in response to SDF-1 or IP-10, in the presence or absence of collagen type I coating, and with or without treatment with the anti-$\beta_1$-integrin blocking mAb. Data are shown as mean and SD of three independent experiments. D, Migrational activity of activated PBTs and tumor-derived T cells with or without treatment with the anti-$\beta_1$-integrin blocking mAb, in a collagen type I matrix, in the presence of a chemokine gradient. The percentage of migrating cells/total cells is shown. Data show a representative experiment. E, Directional migration of activated PBTs in a collagen type I matrix in the presence of a chemokine gradient. Colored lines represent individual cells. The percentage of cells oriented towards the chemokine-containing chamber ($= -x$) is depicted. Combined data from two independent experiments are shown.

**Figure 6.** High-density collagen networks impede T cell–tumor cell contact in PDAC. A, Representative images of LSCM. Arrow 1 indicates an area of densely packed collagen around a tumor cluster. Arrow 2 indicates loosely arranged collagen structures in the T-cell area. B, Representative images of SHG microscopy. C,
Quantitative comparison of collagen density in tumor versus T-cell areas. Data shown as the mean gray values and SD. $P < 0.05$. D, Migrational activity of non-activated PBTs, activated PBTs, and tumor-derived T cells in collagen type I matrices of various densities (0.5–1.5 mg/mL) with uniform chemokine concentrations. Data show the distance ($\Delta z$) from the matrix surface to the migration front after 3 h, or the number of cells at $\Delta z = 1$ mm after 12 h of one representative experiment performed in triplicate ($n = 2$).
A. 

![Bar chart showing CD3+ stroma and CD3+ tumor infiltration scores.](image)

B. 

![Images of tissue sections labeled grade 1, grade 2, and grade 3.](image)
A. qRT-PCR

<table>
<thead>
<tr>
<th></th>
<th>CXCR4</th>
<th>CXCR3</th>
<th>CCR5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copy number (x100)</td>
<td>12.0 **</td>
<td>0.8 **</td>
<td>0.6</td>
</tr>
</tbody>
</table>

Pancreas ■ Tumor

B. Tumor-derived day 0 vs Tumor-derived day 14

<table>
<thead>
<tr>
<th>CD4</th>
<th>CD8</th>
</tr>
</thead>
<tbody>
<tr>
<td>10^5</td>
<td>10^5</td>
</tr>
</tbody>
</table>

CD45RO

C. Tumor-derived day 0 vs Tumor-derived day 14

<table>
<thead>
<tr>
<th>CD4</th>
<th>CD8</th>
</tr>
</thead>
<tbody>
<tr>
<td>10^5</td>
<td>10^5</td>
</tr>
</tbody>
</table>

CXCR4

<table>
<thead>
<tr>
<th>Control</th>
<th>Anti-CXCR4 mAb</th>
</tr>
</thead>
</table>

CXCR3

<table>
<thead>
<tr>
<th>Control</th>
<th>Anti-CXCR3 mAb</th>
</tr>
</thead>
</table>

CCR5

<table>
<thead>
<tr>
<th>Control</th>
<th>Anti-CCR5 mAb</th>
</tr>
</thead>
</table>
**Fig. 3**

A. qRT-PCR

<table>
<thead>
<tr>
<th></th>
<th>SDF-1</th>
<th>IP-10</th>
<th>MIP-1β</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreas</td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
</tr>
<tr>
<td>Tumor</td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
</tr>
</tbody>
</table>

B. BioPlex

<table>
<thead>
<tr>
<th></th>
<th>SDF-1</th>
<th>IP-10</th>
<th>MIP-1β</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreas</td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
</tr>
<tr>
<td>Tumor</td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
</tr>
</tbody>
</table>

C. CD3, CXCR4, CXCR3, CCR5

D. SDF-1α, IP-10, MIP-1β

- **SDF-1α**
  - Pancreas: ![Graph](image)
  - Tumor: ![Graph](image)

- **IP-10**
  - Pancreas: ![Graph](image)
  - Tumor: ![Graph](image)

- **MIP-1β**
  - Pancreas: ![Graph](image)
  - Tumor: ![Graph](image)
A. Migrating cells

<table>
<thead>
<tr>
<th>Condition</th>
<th>Medium</th>
<th>SDF-1</th>
<th>IP-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>- collagen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ collagen</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B. % migrating cells

<table>
<thead>
<tr>
<th>Condition</th>
<th>Medium</th>
<th>SDF-1</th>
<th>IP-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBTna</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBTa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor-derived</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C. %

<table>
<thead>
<tr>
<th>Condition</th>
<th>SDF-1</th>
<th>IP-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>matrix-bound</td>
<td></td>
<td></td>
</tr>
<tr>
<td>soluble</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D. % of control

<table>
<thead>
<tr>
<th>Condition</th>
<th>control</th>
<th>SDF-1</th>
<th>IP-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBTna</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBTa</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

E. y (µM)

<table>
<thead>
<tr>
<th>Condition</th>
<th>PBTna medium</th>
<th>PBTna SDF-1</th>
<th>PBTna IP-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>total: n=9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-x: 33.33%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBTa medium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>total: n=18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-x: 66.67%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor-derived medium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>total: n=20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-x: 40.00%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig. 4
A. Integrin Counts

- Control
- Anti-α2 mAb

α-integrin

Control Anti-β1 mAb

β1-integrin

B. MFI

Untreated Anti-β1

PBT ∼ PBT ∼ Tumor-derived

C. Migrating cells

- collagen + collagen + collagen, anti-β1

Medium SDF-1 IP-10

D. % migrating

- Untreated Anti-β1 mAb

E. % migrating

- Untreated Anti-β1 mAb

IP-10

Fig. 5
**Figure 6**

**A.** CD3, CK7, Collagen I, and Merge images showing cellular and collagen characteristics.

**B.** CD3, CK7, and Collagen (SHG) images highlighting specific markers.

**C.** Analysis of CD3, CK7, and Collagen (SHG) with a bar graph showing mean gray values.

**D.** Collagen density (mg/ml) graphs representing Tumor-derived cells over time (3h and 12h) with PBS, IP-10, and SDF-1 treatments.
Clinical Cancer Research

Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer

Natalie Hartmann, Nathalia A Giese, Thomas Giese, et al.

Clin Cancer Res Published OnlineFirst April 24, 2014.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-2972

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2014/04/24/1078-0432.CCR-13-2972.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.